Quantum BioPharma Ltd.
QNTM
$3.24
-$0.20-5.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.80% | 36.74% | 25.42% | 27.01% | 20.69% |
| Depreciation & Amortization | 5.11% | 8.68% | 11.27% | 5.86% | -4.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.07% | -13.92% | -5.17% | 67.28% | 76.31% |
| Operating Income | 34.07% | 13.92% | 5.17% | -67.28% | -76.31% |
| Income Before Tax | 9.58% | -48.26% | -80.73% | -158.40% | -240.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.58% | -48.26% | -80.73% | -158.40% | -240.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -85.58% | 17.99% | 9.65% | -76.99% | 26.89% |
| Net Income | 6.88% | -49.26% | -84.30% | -178.49% | -261.70% |
| EBIT | 34.07% | 13.92% | 5.17% | -67.28% | -76.31% |
| EBITDA | 35.16% | 14.59% | 5.68% | -70.08% | -80.52% |
| EPS Basic | 57.48% | 45.55% | 41.29% | 26.40% | -11.37% |
| Normalized Basic EPS | 52.79% | 42.56% | 36.36% | 15.88% | 3.67% |
| EPS Diluted | 57.48% | 45.55% | 41.29% | 26.40% | -11.37% |
| Normalized Diluted EPS | 52.79% | 42.56% | 36.36% | 15.88% | 3.67% |
| Average Basic Shares Outstanding | 123.61% | 151.73% | 216.30% | 306.51% | 241.31% |
| Average Diluted Shares Outstanding | 123.61% | 151.73% | 216.30% | 306.51% | 241.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |